Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXemplify 357: axatilimab plus corticosteroids as initial treatment for chronic graft-versus-host disease
2023-510292-65-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Axatilimab plus corticosteroids with Placebo plus corticosteroids (2 arms). Primary endpoint: Event-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2023-510292-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510292-65-00.